Palisade Bio, Inc. (PALI) vs X4 Pharmaceuticals, Inc. (XFOR)
- Palisade Bio, Inc. PALI 1.41 −8.44%
- X4 Pharmaceuticals, Inc. XFOR 2.59 −1.89%
Palisade Bio, Inc. and X4 Pharmaceuticals, Inc. are both Biotechnology companies. Palisade Bio, Inc. and X4 Pharmaceuticals, Inc. are of similar size ($268.4M and $261.8M). X4 Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Palisade Bio, Inc. trades at 2.2×. Palisade Bio, Inc. grew revenue faster over the last twelve months: 5,492.6% against −51.7%. X4 Pharmaceuticals, Inc. has the higher net margin (−568.8% vs −4,230.6%) and the lower return on invested capital (−226.6% vs 0.00%). Across the 17 metrics below, Palisade Bio, Inc. leads on 9 and X4 Pharmaceuticals, Inc. on 8.
Valuation
Profitability
| Metric | PALI | XFOR | Biotechnology median |
|---|---|---|---|
| Gross margin | 95.63% | 81.51% | 65.16% |
| Operating margin | (4,681.99%) | (554.71%) | 0.00% |
| Net margin | (4,230.60%) | (568.80%) | 0.00% |
| Free cash flow margin | (2,409.27%) | (559.95%) | 0.00% |
| Return on equity | (51.37%) | (113.08%) | (56.36%) |
| Return on assets | (47.68%) | (50.32%) | (48.04%) |
| Return on invested capital | 0.00% | (226.62%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack